Search Results - "Angiogenesis Inhibitors"

Cardiovascular Safety of VIAN-c4551, an Antiangiogenic Peptide Derived From Vasoinhibin.

Authors: García-González MA Miguel-Martínez AD González-Hernández A et al.

Source: Drug development research [Drug Dev Res] 2025 Nov; Vol. 86 (7), pp. e70177.

Publication Type: Journal Article

Journal Info: Publisher: Wiley-Liss Country of Publication: United States NLM ID: 8204468 Publication Model: Print Cited Medium: Internet ISSN: 1098-2299 (Electronic) Linking ISSN: 02724391 NLM ISO Abbreviation: Drug Dev Res Subsets: MEDLINE

MeSH Terms: Angiogenesis Inhibitors*/adverse effects , Angiogenesis Inhibitors*/pharmacology , Angiogenesis Inhibitors*/administration & dosage, Animals ; Male ; Nitric Oxide Synthase Type III/metabolism ; Nitric Oxide Synthase Type III/antagonists & inhibitors ; Rats ; Humans ; Blood Pressure/drug effects ; Rats, Sprague-Dawley ; Heart Rate/drug effects ; Human Umbilical Vein Endothelial Cells/drug effects ; Lung/drug effects ; Lung/metabolism ; Cells, Cultured ; Phosphorylation/drug effects ; Vasodilation/drug effects ; Acetylcholine/pharmacology

Inflammatory responsive hydrogels incorporated with bevacizumab-loaded infinite coordination nanopolymers for accelerating cartilage repair.

Authors: Chen H Tao X Liu J et al.

Source: Journal of colloid and interface science [J Colloid Interface Sci] 2025 Dec 15; Vol. 700 (Pt 3), pp. 138484. Date of Electronic Publication: 2025 Jul 25.

Publication Type: Journal Article

Journal Info: Publisher: Academic Press Country of Publication: United States NLM ID: 0043125 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1095-7103 (Electronic) Linking ISSN: 00219797 NLM ISO Abbreviation: J Colloid Interface Sci Subsets: MEDLINE

MeSH Terms: Hydrogels*/chemistry , Hydrogels*/pharmacology , Bevacizumab*/chemistry , Bevacizumab*/pharmacology , Bevacizumab*/administration & dosage , Cartilage*/drug effects , Angiogenesis Inhibitors*/pharmacology , Angiogenesis Inhibitors*/chemistry, Rabbits ; Humans ; Animals ; Human Umbilical Vein Endothelial Cells/drug effects ; Cell Proliferation/drug effects ; Mesenchymal Stem Cells/drug effects ; Mesenchymal Stem Cells/cytology ; Chondrocytes/drug effects ; Chondrocytes/cytology ; Inflammation/drug therapy ; Cell Differentiation/drug effects ; Cells, Cultured ; Particle Size ; Drug Liberation

Multifunctional macrophage membrane biomimetic nanoparticles for targeted therapy of neovascular age-related macular degeneration.

Authors: Yin Q Xie Y Chen R et al.

Source: Journal of controlled release : official journal of the Controlled Release Society [J Control Release] 2025 Dec 10; Vol. 388 (Pt 2), pp. 114394. Date of Electronic Publication: 2025 Nov 07.

Publication Type: Journal Article

Journal Info: Publisher: Elsevier Science Publishers Country of Publication: Netherlands NLM ID: 8607908 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-4995 (Electronic) Linking ISSN: 01683659 NLM ISO Abbreviation: J Control Release Subsets: MEDLINE

MeSH Terms: Macular Degeneration*/drug therapy , Macular Degeneration*/pathology , Nanoparticles*/administration & dosage , Nanoparticles*/chemistry , Choroidal Neovascularization*/drug therapy , Choroidal Neovascularization*/pathology , Biomimetic Materials*/administration & dosage , Biomimetic Materials*/chemistry , Macrophages*/metabolism , Curcumin*/administration & dosage , Curcumin*/therapeutic use , Curcumin*/chemistry , Angiogenesis Inhibitors*/administration & dosage , Angiogenesis Inhibitors*/therapeutic use , Anti-Inflammatory Agents*/administration & dosage , Anti-Inflammatory Agents*/therapeutic use, Animals ; Mice, Inbred C57BL ; Mice ; Polylactic Acid-Polyglycolic Acid Copolymer/chemistry ; Humans ; Male ; Oxidative Stress/drug effects ; Antioxidants/administration & dosage ; Disease Models, Animal

Angiogenesis Inhibitors and Arterial Dissection or Aneurysm in Patients With Metastatic Colorectal Cancer.

Authors: Singier A Jarne Munoz A Maumus-Robert S et al.

Source: JAMA network open [JAMA Netw Open] 2025 Dec 01; Vol. 8 (12), pp. e2546960. Date of Electronic Publication: 2025 Dec 01.

Publication Type: Journal Article

Journal Info: Publisher: American Medical Association Country of Publication: United States NLM ID: 101729235 Publication Model: Electronic Cited Medium: Internet ISSN: 2574-3805 (Electronic) Linking ISSN: 25743805 NLM ISO Abbreviation: JAMA Netw Open Subsets: MEDLINE

MeSH Terms: Colorectal Neoplasms*/drug therapy , Colorectal Neoplasms*/pathology , Angiogenesis Inhibitors*/adverse effects , Angiogenesis Inhibitors*/therapeutic use , Aortic Dissection*/epidemiology , Aortic Dissection*/chemically induced , Aneurysm*/epidemiology , Aneurysm*/chemically induced, Humans ; Male ; Female ; Middle Aged ; Case-Control Studies ; Aged ; France/epidemiology ; Bevacizumab/adverse effects ; Bevacizumab/therapeutic use ; Antibodies, Monoclonal, Humanized/adverse effects ; Antibodies, Monoclonal, Humanized/therapeutic use ; Ramucirumab ; Adult ; Dissection, Blood Vessel ; Phenylurea Compounds ; Pyridines

Angiogenesis and thymic epithelial tumors: from preclinical insights to different therapeutic lines and combination strategies.

Authors: Miliziano D Sciortino C Manglaviti S et al.

Source: Cancer treatment reviews [Cancer Treat Rev] 2025 Dec; Vol. 141, pp. 103049. Date of Electronic Publication: 2025 Nov 13.

Publication Type: Journal Article; Review

Journal Info: Publisher: Elsevier Country of Publication: Netherlands NLM ID: 7502030 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-1967 (Electronic) Linking ISSN: 03057372 NLM ISO Abbreviation: Cancer Treat Rev Subsets: MEDLINE

MeSH Terms: Thymus Neoplasms*/drug therapy , Thymus Neoplasms*/blood supply , Thymus Neoplasms*/pathology , Neovascularization, Pathologic*/drug therapy , Angiogenesis Inhibitors*/therapeutic use , Angiogenesis Inhibitors*/administration & dosage , Neoplasms, Glandular and Epithelial*/drug therapy , Neoplasms, Glandular and Epithelial*/blood supply , Neoplasms, Glandular and Epithelial*/pathology , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use, Humans ; Animals ; Angiogenesis

SCR Disease Name: Thymic epithelial tumor

Recent progress in the exploitation of anti-cancer small molecules targeting angiogenesis.

Authors: Zheng Y Qiu H Zhang K et al.

Source: Journal of enzyme inhibition and medicinal chemistry [J Enzyme Inhib Med Chem] 2025 Dec; Vol. 40 (1), pp. 2584811. Date of Electronic Publication: 2025 Nov 20.

Publication Type: Journal Article; Review

Journal Info: Publisher: Taylor & Francis Country of Publication: England NLM ID: 101150203 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1475-6374 (Electronic) Linking ISSN: 14756366 NLM ISO Abbreviation: J Enzyme Inhib Med Chem Subsets: MEDLINE

MeSH Terms: Angiogenesis Inhibitors*/pharmacology , Angiogenesis Inhibitors*/chemistry , Angiogenesis Inhibitors*/chemical synthesis , Neovascularization, Pathologic*/drug therapy , Neovascularization, Pathologic*/metabolism , Neovascularization, Pathologic*/pathology , Antineoplastic Agents*/pharmacology , Antineoplastic Agents*/chemistry , Antineoplastic Agents*/chemical synthesis , Small Molecule Libraries*/pharmacology , Small Molecule Libraries*/chemistry , Small Molecule Libraries*/chemical synthesis , Neoplasms*/drug therapy , Neoplasms*/pathology , Neoplasms*/blood supply, Humans ; Structure-Activity Relationship ; Molecular Structure ; Cell Proliferation/drug effects ; Animals ; Apoptosis/drug effects ; Drug Screening Assays, Antitumor ; Angiogenesis

Discovery of novel aniline-pyrimidine analogues as orally bioavailable dual VEGFR-2/tubulin inhibitors with potent antitumor and anti-angiogenesis efficacy.

Authors: Chu Y Huang G Yao Y et al.

Source: Bioorganic chemistry [Bioorg Chem] 2025 Dec; Vol. 167, pp. 109233. Date of Electronic Publication: 2025 Nov 15.

Publication Type: Journal Article

Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 1303703 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1090-2120 (Electronic) Linking ISSN: 00452068 NLM ISO Abbreviation: Bioorg Chem Subsets: MEDLINE

MeSH Terms: Antineoplastic Agents*/pharmacology , Antineoplastic Agents*/chemistry , Antineoplastic Agents*/chemical synthesis , Antineoplastic Agents*/administration & dosage , Angiogenesis Inhibitors*/pharmacology , Angiogenesis Inhibitors*/chemistry , Angiogenesis Inhibitors*/chemical synthesis , Angiogenesis Inhibitors*/administration & dosage , Vascular Endothelial Growth Factor Receptor-2*/antagonists & inhibitors , Vascular Endothelial Growth Factor Receptor-2*/metabolism , Tubulin*/metabolism , Pyrimidines*/pharmacology , Pyrimidines*/chemistry , Pyrimidines*/administration & dosage , Pyrimidines*/chemical synthesis , Aniline Compounds*/chemistry , Aniline Compounds*/pharmacology , Aniline Compounds*/administration & dosage , Tubulin Modulators*/pharmacology , Tubulin Modulators*/chemistry , Tubulin Modulators*/chemical synthesis , Tubulin Modulators*/administration & dosage , Drug Discovery* , Protein Kinase Inhibitors*/pharmacology , Protein Kinase Inhibitors*/chemistry , Protein Kinase Inhibitors*/chemical synthesis, Humans ; Animals ; Cell Proliferation/drug effects ; Drug Screening Assays, Antitumor ; Zebrafish ; Structure-Activity Relationship ; Molecular Structure ; Dose-Response Relationship, Drug ; Administration, Oral ; Human Umbilical Vein Endothelial Cells ; Apoptosis/drug effects ; Cell Line, Tumor

FYB-201 Biosimilar ranibizumab (Ongavia/Ranivisio/Cimerli) Efficacy and Safety in Clinical Settings - FORCE study.

Authors: Sharma A Nicholson L Vazquez-Alfageme C et al.

Corporate Authors: Sharma A Nicholson L Vazquez-Alfageme C et al.

Source: Eye (London, England) [Eye (Lond)] 2025 Dec; Vol. 39 (17), pp. 3129-3134. Date of Electronic Publication: 2025 Oct 02.

Publication Type: Journal Article; Multicenter Study

Journal Info: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 8703986 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5454 (Electronic) Linking ISSN: 0950222X NLM ISO Abbreviation: Eye (Lond) Subsets: MEDLINE

MeSH Terms: Ranibizumab*/therapeutic use , Ranibizumab*/adverse effects , Ranibizumab*/administration & dosage , Biosimilar Pharmaceuticals*/therapeutic use , Biosimilar Pharmaceuticals*/adverse effects , Biosimilar Pharmaceuticals*/administration & dosage , Angiogenesis Inhibitors*/therapeutic use , Angiogenesis Inhibitors*/adverse effects , Angiogenesis Inhibitors*/administration & dosage, Humans ; Female ; Male ; Retrospective Studies ; Intravitreal Injections ; Visual Acuity/physiology ; Aged ; Middle Aged ; Aged, 80 and over ; Vascular Endothelial Growth Factor A/antagonists & inhibitors ; Treatment Outcome ; Macular Edema/drug therapy ; Tomography, Optical Coherence

Real-world treatment patterns and visual outcomes of faricimab in patients with diabetic macular oedema in the UK at 12 months: the FARWIDE-DMO study.

Authors: Peto T Pearce I Talks J et al.

Source: Eye (London, England) [Eye (Lond)] 2025 Dec; Vol. 39 (18), pp. 3350-3358. Date of Electronic Publication: 2025 Oct 23.

Publication Type: Journal Article; Multicenter Study

Journal Info: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 8703986 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5454 (Electronic) Linking ISSN: 0950222X NLM ISO Abbreviation: Eye (Lond) Subsets: MEDLINE

MeSH Terms: Visual Acuity* , Diabetic Retinopathy*/drug therapy , Diabetic Retinopathy*/physiopathology , Diabetic Retinopathy*/complications , Diabetic Retinopathy*/diagnosis , Macular Edema*/drug therapy , Macular Edema*/physiopathology , Macular Edema*/etiology , Macular Edema*/diagnosis , Angiogenesis Inhibitors*/administration & dosage , Angiogenesis Inhibitors*/therapeutic use, Humans ; Female ; Male ; Intravitreal Injections ; United Kingdom/epidemiology ; Aged ; Middle Aged ; Treatment Outcome ; Follow-Up Studies ; Vascular Endothelial Growth Factor A/antagonists & inhibitors ; Retrospective Studies ; Time Factors ; Tomography, Optical Coherence ; Antibodies, Bispecific

COMPARISON OF CHARACTERISTICS AND TREATMENT OUTCOMES OF TYPE 1 AND TYPE 2 MYOPIC CHOROIDAL NEOVASCULARIZATION AFTER ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY.

Authors: Tew TB Hsieh YT Tsui MC et al.

Source: Retina (Philadelphia, Pa.) [Retina] 2025 Dec 01; Vol. 45 (12), pp. 2279-2288.

Publication Type: Journal Article; Comparative Study

Journal Info: Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 8309919 Publication Model: Print Cited Medium: Internet ISSN: 1539-2864 (Electronic) Linking ISSN: 0275004X NLM ISO Abbreviation: Retina Subsets: MEDLINE

MeSH Terms: Angiogenesis Inhibitors*/therapeutic use , Angiogenesis Inhibitors*/administration & dosage , Visual Acuity*/physiology , Choroidal Neovascularization*/drug therapy , Choroidal Neovascularization*/diagnosis , Choroidal Neovascularization*/etiology , Myopia, Degenerative*/complications , Myopia, Degenerative*/drug therapy , Myopia, Degenerative*/diagnosis , Ranibizumab*/administration & dosage , Ranibizumab*/therapeutic use , Bevacizumab*/administration & dosage , Bevacizumab*/therapeutic use, Humans ; Retrospective Studies ; Female ; Male ; Tomography, Optical Coherence/methods ; Intravitreal Injections ; Vascular Endothelial Growth Factor A/antagonists & inhibitors ; Middle Aged ; Fluorescein Angiography/methods ; Aged ; Treatment Outcome ; Follow-Up Studies ; Fundus Oculi ; Adult

Clinical characteristics and treatment outcomes of bilateral myopic macular neovascularization in high myopic patients.

Authors: Lim SH Bae K Yoon CK et al.

Source: Acta ophthalmologica [Acta Ophthalmol] 2025 Dec; Vol. 103 (8), pp. 1049-1057. Date of Electronic Publication: 2025 Aug 05.

Publication Type: Journal Article

Journal Info: Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 101468102 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1755-3768 (Electronic) Linking ISSN: 1755375X NLM ISO Abbreviation: Acta Ophthalmol Subsets: MEDLINE

MeSH Terms: Myopia, Degenerative*/complications , Myopia, Degenerative*/diagnosis , Myopia, Degenerative*/physiopathology , Visual Acuity* , Angiogenesis Inhibitors*/administration & dosage , Angiogenesis Inhibitors*/therapeutic use , Choroidal Neovascularization*/diagnosis , Choroidal Neovascularization*/etiology , Choroidal Neovascularization*/drug therapy , Macula Lutea*/pathology , Retinal Neovascularization*/diagnosis , Retinal Neovascularization*/etiology , Retinal Neovascularization*/drug therapy , Refraction, Ocular*/physiology, Humans ; Female ; Retrospective Studies ; Middle Aged ; Male ; Tomography, Optical Coherence/methods ; Follow-Up Studies ; Fluorescein Angiography/methods ; Treatment Outcome ; Intravitreal Injections ; Vascular Endothelial Growth Factor A/antagonists & inhibitors ; Adult ; Ranibizumab/administration & dosage ; Fundus Oculi ; Aged ; Bevacizumab/administration & dosage

Association between intravitreal anti-vascular endothelial growth factor agents and hypertension: a meta-analysis.

Authors: Balas M Jhaveri A Khalid F et al.

Source: Canadian journal of ophthalmology. Journal canadien d'ophtalmologie [Can J Ophthalmol] 2025 Dec; Vol. 60 (6), pp. e888-e897. Date of Electronic Publication: 2025 Jun 16.

Publication Type: Journal Article; Meta-Analysis; Systematic Review

Journal Info: Publisher: Elsevier Country of Publication: England NLM ID: 0045312 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1715-3360 (Electronic) Linking ISSN: 00084182 NLM ISO Abbreviation: Can J Ophthalmol Subsets: MEDLINE

MeSH Terms: Hypertension*/chemically induced , Hypertension*/epidemiology , Hypertension*/physiopathology , Angiogenesis Inhibitors*/adverse effects , Angiogenesis Inhibitors*/administration & dosage , Vascular Endothelial Growth Factor A*/antagonists & inhibitors, Humans ; Intravitreal Injections ; Ranibizumab/adverse effects ; Ranibizumab/administration & dosage ; Randomized Controlled Trials as Topic ; Receptors, Vascular Endothelial Growth Factor ; Recombinant Fusion Proteins

Real-world outcomes of early and deferred anti-VEGF treatment in diabetic macular oedema in patients with type 1 diabetes.

Authors: Wirkkala J Kubin AM Ohtonen P et al.

Source: Annals of medicine [Ann Med] 2025 Dec; Vol. 57 (1), pp. 2530218. Date of Electronic Publication: 2025 Jul 09.

Publication Type: Journal Article

Journal Info: Publisher: Informa Healthcare Country of Publication: England NLM ID: 8906388 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2060 (Electronic) Linking ISSN: 07853890 NLM ISO Abbreviation: Ann Med Subsets: MEDLINE

MeSH Terms: Diabetes Mellitus, Type 1*/complications , Macular Edema*/drug therapy , Macular Edema*/etiology , Diabetic Retinopathy*/drug therapy , Diabetic Retinopathy*/etiology , Angiogenesis Inhibitors*/administration & dosage , Angiogenesis Inhibitors*/therapeutic use , Vascular Endothelial Growth Factor A*/antagonists & inhibitors, Humans ; Male ; Female ; Retrospective Studies ; Intravitreal Injections ; Visual Acuity/drug effects ; Adult ; Middle Aged ; Treatment Outcome ; Ranibizumab/administration & dosage ; Bevacizumab/administration & dosage

Disparities in Presentation and Anti-VEGF Therapy Initiation for Neovascular Age-Related Macular Degeneration: An Analysis of the Academy IRIS® Registry (Intelligent Research in Sight).

Authors: Acharya B Momenaei B Zhang Q et al.

Corporate Authors: Acharya B Momenaei B Zhang Q et al.

Source: Ophthalmology [Ophthalmology] 2025 Dec; Vol. 132 (12), pp. 1411-1421. Date of Electronic Publication: 2025 Jul 28.

Publication Type: Journal Article; Multicenter Study

Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 7802443 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1549-4713 (Electronic) Linking ISSN: 01616420 NLM ISO Abbreviation: Ophthalmology Subsets: MEDLINE

MeSH Terms: Angiogenesis Inhibitors*/therapeutic use , Angiogenesis Inhibitors*/administration & dosage , Registries* , Visual Acuity*/physiology , Wet Macular Degeneration*/drug therapy , Wet Macular Degeneration*/diagnosis , Wet Macular Degeneration*/physiopathology , Wet Macular Degeneration*/ethnology , Healthcare Disparities*/statistics & numerical data , Ranibizumab*/administration & dosage , Ranibizumab*/therapeutic use , Bevacizumab*/administration & dosage , Bevacizumab*/therapeutic use, Humans ; Male ; Female ; Retrospective Studies ; Intravitreal Injections ; Vascular Endothelial Growth Factor A/antagonists & inhibitors ; Aged ; Middle Aged ; Aged, 80 and over ; United States/epidemiology ; Academies and Institutes ; Receptors, Vascular Endothelial Growth Factor

Cost-minimisation analysis of anti-VEGF therapies in neovascular age-related macular degeneration and diabetic macular oedema in Switzerland.

Authors: Ambresin A Quist SW Boer M et al.

Source: Journal of medical economics [J Med Econ] 2025 Dec; Vol. 28 (1), pp. 1198-1213. Date of Electronic Publication: 2025 Jul 29.

Publication Type: Journal Article

Journal Info: Publisher: Taylor & Francis Country of Publication: England NLM ID: 9892255 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1941-837X (Electronic) Linking ISSN: 13696998 NLM ISO Abbreviation: J Med Econ Subsets: MEDLINE

MeSH Terms: Macular Edema*/drug therapy , Macular Edema*/economics , Angiogenesis Inhibitors*/economics , Angiogenesis Inhibitors*/therapeutic use , Angiogenesis Inhibitors*/administration & dosage , Macular Degeneration*/drug therapy , Vascular Endothelial Growth Factor A*/antagonists & inhibitors , Diabetic Retinopathy*/drug therapy, Humans ; Recombinant Fusion Proteins/economics ; Recombinant Fusion Proteins/therapeutic use ; Recombinant Fusion Proteins/administration & dosage ; Switzerland ; Receptors, Vascular Endothelial Growth Factor/therapeutic use ; Receptors, Vascular Endothelial Growth Factor/administration & dosage ; Ranibizumab/economics ; Ranibizumab/therapeutic use ; Ranibizumab/administration & dosage ; Biosimilar Pharmaceuticals/economics ; Biosimilar Pharmaceuticals/therapeutic use ; Biosimilar Pharmaceuticals/administration & dosage ; Models, Econometric ; Aged ; Male ; Intravitreal Injections ; Female

Potential VEGFR2 inhibitors for managing metastatic cervical cancer: insights from molecular dynamics and free energy landscape studies.

Authors: Alobaida A Abouzied AS Taslim Ahmed A et al.

Source: Molecular diversity [Mol Divers] 2025 Dec; Vol. 29 (6), pp. 5523-5541. Date of Electronic Publication: 2024 Dec 18.

Publication Type: Journal Article

Journal Info: Publisher: ESCOM Science Publishers Country of Publication: Netherlands NLM ID: 9516534 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-501X (Electronic) Linking ISSN: 13811991 NLM ISO Abbreviation: Mol Divers Subsets: MEDLINE

MeSH Terms: Vascular Endothelial Growth Factor Receptor-2*/antagonists & inhibitors , Vascular Endothelial Growth Factor Receptor-2*/chemistry , Vascular Endothelial Growth Factor Receptor-2*/metabolism , Uterine Cervical Neoplasms*/drug therapy , Uterine Cervical Neoplasms*/pathology , Uterine Cervical Neoplasms*/metabolism , Molecular Dynamics Simulation* , Angiogenesis Inhibitors*/chemistry , Angiogenesis Inhibitors*/pharmacology , Protein Kinase Inhibitors*/chemistry , Protein Kinase Inhibitors*/pharmacology, Humans ; Female ; Molecular Docking Simulation ; Thermodynamics ; Neoplasm Metastasis

Cost-effectiveness analysis of bispecific antibody faricimab for treatment of neovascular age-related macular degeneration and diabetic macular edema in Japan.

Authors: Yanagi Y Tsujimura J Ohno S et al.

Source: Journal of medical economics [J Med Econ] 2025 Dec; Vol. 28 (1), pp. 448-459. Date of Electronic Publication: 2025 Mar 23.

Publication Type: Journal Article

Journal Info: Publisher: Taylor & Francis Country of Publication: England NLM ID: 9892255 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1941-837X (Electronic) Linking ISSN: 13696998 NLM ISO Abbreviation: J Med Econ Subsets: MEDLINE

MeSH Terms: Macular Edema*/drug therapy , Angiogenesis Inhibitors*/economics , Angiogenesis Inhibitors*/therapeutic use , Diabetic Retinopathy*/drug therapy , Antibodies, Bispecific*/economics , Antibodies, Bispecific*/therapeutic use , Macular Degeneration*/drug therapy, Humans ; Cost-Benefit Analysis ; Markov Chains ; Japan ; Quality-Adjusted Life Years ; Ranibizumab/economics ; Ranibizumab/therapeutic use ; Recombinant Fusion Proteins/economics ; Recombinant Fusion Proteins/therapeutic use ; Aged ; Receptors, Vascular Endothelial Growth Factor/therapeutic use ; Antibodies, Monoclonal, Humanized/economics ; Antibodies, Monoclonal, Humanized/therapeutic use ; Male ; Female ; Cost-Effectiveness Analysis

Clinical Efficacy of Switching to Faricimab in Treatment Resistant Neovascular Age-Related Macular Degeneration: Systematic Review and Meta-analysis.

Authors: Zhang C Aboukasm G Lai DA et al.

Source: American journal of ophthalmology [Am J Ophthalmol] 2025 Dec; Vol. 280, pp. 248-266. Date of Electronic Publication: 2025 Aug 21.

Publication Type: Journal Article; Systematic Review; Meta-Analysis; Review

Journal Info: Publisher: Elsevier Science Country of Publication: United States NLM ID: 0370500 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-1891 (Electronic) Linking ISSN: 00029394 NLM ISO Abbreviation: Am J Ophthalmol Subsets: MEDLINE

MeSH Terms: Angiogenesis Inhibitors*/therapeutic use , Angiogenesis Inhibitors*/administration & dosage , Wet Macular Degeneration*/drug therapy , Wet Macular Degeneration*/physiopathology , Wet Macular Degeneration*/diagnosis , Drug Substitution* , Antibodies, Monoclonal, Humanized*/therapeutic use , Antibodies, Monoclonal, Humanized*/administration & dosage, Humans ; Intravitreal Injections ; Visual Acuity ; Vascular Endothelial Growth Factor A/antagonists & inhibitors ; Treatment Outcome ; Tomography, Optical Coherence ; Antibodies, Bispecific

Low-molecular-weight dextran sulfate sodium as novel heparanase inhibitor preventing breast cancer metastasis in mice by inhibiting migration and angiogenesis.

Authors: Mo Y Song G Fu L et al.

Source: Carbohydrate polymers [Carbohydr Polym] 2025 Dec 01; Vol. 369, pp. 124255. Date of Electronic Publication: 2025 Aug 22.

Publication Type: Journal Article

Journal Info: Publisher: Elsevier Applied Science Publishers Country of Publication: England NLM ID: 8307156 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-1344 (Electronic) Linking ISSN: 01448617 NLM ISO Abbreviation: Carbohydr Polym Subsets: MEDLINE

MeSH Terms: Glucuronidase*/antagonists & inhibitors , Glucuronidase*/metabolism , Breast Neoplasms*/drug therapy , Breast Neoplasms*/pathology , Breast Neoplasms*/metabolism , Dextran Sulfate*/pharmacology , Dextran Sulfate*/chemistry , Dextran Sulfate*/therapeutic use , Neovascularization, Pathologic*/drug therapy , Enzyme Inhibitors*/pharmacology , Enzyme Inhibitors*/chemistry , Antineoplastic Agents*/pharmacology , Antineoplastic Agents*/chemistry , Angiogenesis Inhibitors*/pharmacology , Angiogenesis Inhibitors*/chemistry, Animals ; Humans ; Female ; Cell Movement/drug effects ; Mice ; Human Umbilical Vein Endothelial Cells/drug effects ; Cell Line, Tumor ; Molecular Weight ; Mice, Inbred BALB C ; Neoplasm Metastasis/prevention & control ; Epithelial-Mesenchymal Transition/drug effects ; Angiogenesis

Real-World Outcomes in Eyes With Neovascular AMD Switched From Brolucizumab to Faricimab: A TRUCKEE Study Analysis.

Authors: Soylu C Corradetti G Alhelaly M et al.

Source: American journal of ophthalmology [Am J Ophthalmol] 2025 Dec; Vol. 280, pp. 169-175. Date of Electronic Publication: 2025 Aug 13.

Publication Type: Journal Article; Multicenter Study

Journal Info: Publisher: Elsevier Science Country of Publication: United States NLM ID: 0370500 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-1891 (Electronic) Linking ISSN: 00029394 NLM ISO Abbreviation: Am J Ophthalmol Subsets: MEDLINE

MeSH Terms: Visual Acuity*/physiology , Angiogenesis Inhibitors*/therapeutic use , Angiogenesis Inhibitors*/administration & dosage , Wet Macular Degeneration*/drug therapy , Wet Macular Degeneration*/physiopathology , Wet Macular Degeneration*/diagnosis , Antibodies, Monoclonal, Humanized*/therapeutic use , Antibodies, Monoclonal, Humanized*/administration & dosage, Humans ; Retrospective Studies ; Male ; Female ; Intravitreal Injections ; Aged ; Treatment Outcome ; Aged, 80 and over ; Vascular Endothelial Growth Factor A/antagonists & inhibitors ; Tomography, Optical Coherence ; Drug Substitution ; Follow-Up Studies ; Fluorescein Angiography ; Middle Aged ; Antibodies, Bispecific